From a Chinese healthcare system perspective, triple therapy with finerenone, SGLT2i and SoC demonstrates superior cost-effectiveness compared to either finerenone or SGLT2i as add-ons to SoC in patients with T2D and CKD. The gene discussed is UBXN11; the disease is chronic kidney disease.